Hidrasec (Racecadotril)

Hidrasec is indicated for the short‑term management of acute, non‑bloody diarrhea in both pediatric and adult patients. The medication is taken orally and works locally in the gut, making it suitable for use alongside standard rehydration measures.

• Relief of watery stools associated with viral gastroenteritis.
• Adjunct therapy for travel‑related diarrhea when rehydration is needed.
• Symptomatic control in mild to moderate diarrheal episodes caused by food‑borne infections.
• Use in patients where opioid‑based antidiarrheals are contraindicated.
• Management of diarrhea in patients undergoing oral rehydration therapy to reduce fluid loss.
• Supportive care for diarrheal episodes in elderly individuals with comorbidities.

• Racecadotril, the active component of Hidrasec, is a peripheral enkephalinase inhibitor. By blocking the enzyme that degrades endogenous enkephalins, it increases the concentration of these peptides in the intestinal mucosa. The elevated enkephalins activate opioid receptors on enteric neurons, which reduces secretion of water and electrolytes into the intestinal lumen without altering intestinal motility, thereby decreasing stool output and helps restore normal fluid balance.

Adverse reactions to Hidrasec are generally uncommon, but they can be grouped by how often they occur and by the seriousness of the event.

Common

• Nausea or mild stomach discomfort, usually transient and not requiring medical intervention.
• Headache, which is typically mild and resolves without treatment.
• Transient abdominal cramps that may accompany the underlying diarrheal condition.
• Dizziness or light‑headed feeling, often occurring shortly after the first dose.

Serious

• Allergic skin reactions such as rash, itching, or urticaria that may indicate a hypersensitivity response.
• Severe hypersensitivity including anaphylactic reactions, characterized by swelling, difficulty breathing, or drop in blood pressure and requiring immediate medical care.

When considering Hidrasec, certain precautionary measures should be observed to ensure safe use and to minimize risk.

• Verify that diarrhea is not caused by invasive bacterial infection or dysentery before use.
• Use only for short‑term relief; prolonged use may mask underlying disease.
• Ensure adequate fluid and electrolyte replacement alongside the medication.
• Consult a healthcare professional before giving Hidrasec to infants younger than six months.
• Avoid use in patients with known hypersensitivity to racecadotril or any excipients.
• Caution in patients with severe renal impairment, as dosing adjustments may be required.

Hidrasec may interact with other medicines; awareness of potential interactions helps avoid reduced efficacy or increased adverse effects.

Avoid

• Concomitant use with potent opioid analgesics, which could enhance central opioid effects.
• Combination with other antidiarrheal agents that act on gut motility, such as loperamide, may lead to excessive reduction of intestinal transit.

Use with caution

• Co‑administration with drugs that are substrates of renal tubular transporters, as renal impairment may affect clearance.
• Use together with antihistamines or sedatives may increase the likelihood of dizziness.
• Caution when given alongside medications that cause electrolyte disturbances, such as certain diuretics, because dehydration from diarrhea can be compounded.